Dr. Greving has a record of innovation with more than 15 years of R&D experience. He is driven by a passion to integrate computation and laboratory technologies to improve biological discovery efficiency. Most recently, Dr. Greving served as Co-Founder and CTO at RubrYc Therapeutics where he led development of an AI-backed antibody discovery engine that …
Dr. DeLong has more than a decade of business development, corporate development, and corporate strategy experience and has guided dozens of companies through transformative deals and challenging strategic decisions. Most recently, he served as head of business development for Tris Pharma, a commercial-stage specialty pharmaceutical company, where he led multiple transactions and mission-critical strategic initiatives …
Dr. Jenkins has three decades of experience in operations, business development and consulting. Before joining iBio, he was Senior Vice President CMC at Ridgeback Therapeutics during BLA preparation and eventual approval of ansuvimab. Prior to Ridgeback, Dr. Jenkins worked as a Senior Consultant at Bioprocessing Technology Consultants where he managed CDMO clients in both cell …
Mr. Banjak joins iBio with over 15 years’ experience in the biotechnology and contract research industries. He previously served as the first general counsel of both Istari Oncology and Dova Pharmaceuticals, leading the legal and compliance functions within both organizations. While at Dova, Mr. Banjak advised the company through a number of clinical and corporate …
Mr. Luter brings over 25 years of experience in the field of information technology. Before joining iBio, he served as Sr. Director, Information Technology – The Americas at Lupin Incorporated, a global pharmaceutical company. During his tenure as Sr. Director, he aligned IT functions across the Brazil, Mexico, U.S., and Canada regions and successfully deployed …